The Food and Drug Administration (FDA) is placing a hold on Novavax's (NVAX) experimental flu-COVID vaccines after a patient reported developing motor neuropathy tied to a vaccine from a phase two trial in 2023. Novavax's stock has plunged by nearly 20%.

Market Domination's Julie Hyman and Josh Lipton report more on this story.

To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

This post was written by Luke Carberry Mogan.